Quanterix Corporation (QTRX)

NASDAQ:QTRX

QTRX

Quanterix

RESEARCH TOOLSreports

Want to see QTRX full AI Analyst Report?

Quanterix (QTRX) Earnings Dates, Call Summary & Reports

376 Followers

Earnings Data

Report Date

Aug 10, 2026

After Close (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

-0.4

Last Year’s EPS

-0.77

Same Quarter Last Year

Analyst Consensus

Hold

Based on 2 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:May 06, 2026|

% Change Since:

Earnings Call Sentiment|Neutral

The call mixed encouraging operational and financial progress—an increase in reported revenue, strong non-GAAP gross margins above 50%, delivery of $85M in synergies, a healthy cash balance (~$102.6M), and clear strategic investments in commercial capabilities and diagnostics (HD-X IVD push, Tempus partnership). Offsetting these positives are material organic revenue declines (Simoa -21%, spatial -26%), a 33% drop in pharma revenue, softer-than-expected instrumentation sales, and notable one-time acquisition-related charges. Management maintained full-year guidance and outlined concrete steps to drive H2 improvement and cash-flow breakeven, but near-term execution and end-market recovery remain key risks.

Company Guidance

Quanterix reiterated full‑year 2026 guidance of $169–$174M in revenue, GAAP gross margin of 41–45% and non‑GAAP gross margin of 49–53%, expects cash‑flow breakeven in H2 2026 and to end the year with ~ $100M cash and no debt, with Q2 revenues "roughly in line to slightly ahead" of Q1. In Q1 the company reported $36.4M revenue (up 20% YoY; organic revenue −21%), gross profit $15.6M (42.7% GAAP margin), non‑GAAP gross profit $18.5M (50.9% non‑GAAP margin), adjusted EBITDA loss of $9.8M (improved $1.5M sequentially), and $102.6M in cash after $19M cash used ($14.7M adjusted). Product detail: Simoa $24M (−21% organic), spatial $12.4M (−26%), instruments $4M (Simoa $2.3M, spatial $1.7M) with 16 Simoa and 11 spatial placements, consumables $21.4M (Simoa $14.5M, spatial $6.9M), and Accelerator lab services $4.3M (Simoa $3.5M, spatial $0.8M); customer mix was ~65% academia, pro‑forma academic revenue down ~16% and pharma revenue down 33%. They reported operating expenses of $56.9M (including ~ $22M acquisition/integration/restructuring/purchase‑accounting costs and a $19M one‑time intangible write‑off), non‑GAAP OPEX $34.7M, delivery of $85M annualized Akoya synergies, and a GAAP accounting reclassification of shipping/handling into gross margin (no change to non‑GAAP expectations).

Total Revenue Growth (Reported)

Total revenue for Q1 2026 was $36.4 million, up 20% year-over-year, driven in part by acquisitions and partner revenue.

Diagnostics Partner Momentum

Revenue from diagnostics partners increased to $2.9 million from $1.6 million in Q1 2025, an increase of approximately 81%, reflecting growing volume for single-biomarker tests from enablement partners.

Strong Installed Base and Market Position

Company reports an installed base of over 2,300 instruments and positions Simoa as a leader in ultrasensitive digital immunoassays and spatial as the highest-plex proteomic platform, which management expects to leverage for growth.

Cost Synergies Delivered

Quanterix delivered the $85 million of annualized cost synergies committed from the Akoya acquisition and will cease reporting these after this quarter.

Robust Non-GAAP Gross Margins

Non-GAAP gross profit was $18.5 million with non-GAAP gross margin at 50.9% in Q1; full-year non-GAAP gross margin guide is 49%–53%.

Improving Adjusted EBITDA and Reduced Adjusted Cash Usage

Adjusted EBITDA was a loss of $9.8 million, a sequential improvement of $1.5 million. Adjusted cash usage in the quarter was $14.7 million, and management expects cash usage to decline as annual payments have passed.

Healthy Cash Position and No Debt

Cash, cash equivalents, marketable securities and restricted cash totaled $102.6 million at quarter end and the company expects to end 2026 with roughly $100 million and no debt.

Strategic Commercial and Diagnostics Investments

Management is investing in commercial effectiveness (senior pharma partnerships leader, expanded lead generation, market development leaders, Thermo Fisher distribution integration) and diagnostics (hiring diagnostics leader, upgrading Simoa HD-X for IVD filing targeted in 2027, lab infrastructure, clinical utility studies).

Partnerships and Product Roadmap Focus

Notable partnership with Tempus AI to integrate LucentAD Complete into select EHR systems; product roadmap streamlined to prioritize HD-X and incorporate learnings from Simoa ONE early access.

Quanterix (QTRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

QTRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 10, 2026	2026 (Q2)	-0.40 / -	-0.77	―	―	―
May 06, 2026	2026 (Q1)	-0.51 / -0.37	-0.53	30.19% (+0.16)
Mar 02, 2026	2025 (Q4)	-0.45 / -0.49	-0.3	-63.33% (-0.19)
Nov 10, 2025	2025 (Q3)	-0.46 / -0.73	-0.219	-233.33% (-0.51)
Aug 07, 2025	2025 (Q2)	-0.42 / -0.77	-0.25	-208.00% (-0.52)
May 12, 2025	2025 (Q1)	-0.43 / -0.53	-0.26	-103.85% (-0.27)
Mar 17, 2025	2024 (Q4)	-0.26 / -0.30	-0.33	9.09% (+0.03)
Nov 12, 2024	2024 (Q3)	-0.24 / -0.22	-0.21	-4.29% (>-0.01)
Aug 08, 2024	2024 (Q2)	-0.27 / -0.25	-0.16	-56.25% (-0.09)
May 07, 2024	2024 (Q1)	-0.31 / -0.26	-0.16	-62.50% (-0.10)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

QTRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 06, 2026	$3.29	$2.75	-16.41%
Mar 02, 2026	$6.33	$5.87	-7.27%
Nov 10, 2025	$5.12	$5.00	-2.34%
Aug 07, 2025	$5.51	$4.75	-13.79%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Quanterix Corporation (QTRX) report earnings?

Quanterix Corporation (QTRX) is schdueled to report earning on Aug 10, 2026, After Close (Confirmed).

What is Quanterix Corporation (QTRX) earnings time?

Quanterix Corporation (QTRX) earnings time is at Aug 10, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is QTRX EPS forecast?

QTRX EPS forecast for the fiscal quarter 2026 (Q2) is -0.4.